Citations

Clear

3053 citation(s) found for "Patel, A".

Comparison of blood culture contamination rates with standard practice versus two blood diversion devices at a single institution
Vieni, Casey , Legried, Michele, Mainella, Jill, Bute, Kelly, Backus, Linda, Sampathkumar, Priya , Schuetz, Audrey N. , Patel, Robin , Karon, Brad S. , Patel, Robin , Schuetz, Audrey N , Mainella, Jill M.

Mayo Clinic

Journal of Clinical Microbiology | June 29, 2026 | Volume: 64 | Issue: 8 | Pages: No page available

10.1128/jcm.00085-26 | PMID 42370687 Get It

ABSTRACT Blood culture contamination can lead to false-positive blood culture results, potentially contributing to increased costs and unneeded antibiotic utilization. Initial specimen diversion devices (ISDD) have been proposed to reduce blood culture contamination rates. A single-center, observational study conducted at Mayo Clinic Rochester compared blood culture contamination rates using Steripath or Kurin ISDDs versus standard blood culture collection protocols. Over 255 phlebotomists were trained in the use of the ISDDs, with 31,215 blood cultures, 410 of which were contaminated, collected from adults in the emergency department and inpatient wards. Baseline contamination rates were 1.29%–2.53% with standard collection methods. The Steripath ISDD with direct-to-media inoculation of blood culture bottles (Steripath-DTM) reduced blood culture contamination compared to standard practice (0.34% vs. 1.43%, respectively, P < 0.001). Follow-up studies with the alternative Steripath configuration with an integrated syringe (Steripath-syringe), and then the Kurin ISDD with syringe collection (Kurin-syringe), did not meet the primary endpoint of <0.5% contamination (Steripath-syringe: 1.28%; Kurin-syringe: 1.76%). All three ISDD configurations failed to meet our goal of >75% utilization, with an average measured utilization of 26% for the Steripath-DTM, 26.4% for the Steripath ISDD (combined DTM and syringe) in a follow-up study, and 41.5% in the Kurin study. Additionally, a survey of phlebotomists revealed low staff satisfaction with both Steripath ISDD configurations. Staff reported multiple ergonomic barriers limiting the Steripath ISDD’s utility, which precluded implementation of the Steripath-DTM in routine clinical practice. IMPORTANCE We conducted a very large, real-world study of two blood diversion devices to determine whether either would meet goals for reduced blood culture contamination and a high rate of utilization by phlebotomists.
Reply to: “Sleep quality is influenced by multiple factors and cannot be reduced to the volume of pineal gland calcification”
Brutto, Óscar H. Del , Mera, Robertino M. , Patel, Vishal , Castillo, Pablo R. , Del Brutto, Oscar H , Castillo, Pablo R

Mayo Clinic

Arquivos de Neuro-Psiquiatria | June 25, 2026 | Volume: 84 | Issue: 05 | Pages: 001-002

10.1055/s-0046-1824434 | PMID 42349858 Get It

Improving Immune Checkpoint Blockade Efficacy in Melanoma Brain Metastases through Myddosomal inhibition with Emavusertib
Roemeling, Christina A. Von , Doonan, Bently P. , Carpenter, Savannah, Patel, Jeet A. , Jobin, Gabriel, Yang, Changlin , Bhatia, A. , Trivedi, Vrunda , Acevedo, A Buylla, Elliott, Tyler , Archibald, Vincent , Speakman, S, Matich, Erica , Mitchell, Duane A. , von Roemeling, Christina A , Carpenter, Savannah L , Jobin, Gabriel W , Bhatia, Alisha , Acevedo, Amanda , Speakman, Skye M , Doonan, Bently , Patel, Jeet A. , Archibald, Vincent

Mayo Clinic

Molecular Cancer Therapeutics | June 24, 2026 | Volume: No volume available | Issue: No issue available | Pages: No page available

10.1158/1535-7163.mct-25-0349 | PMID 42338303 Get It

Abstract Current advances in the treatment of melanoma brain metastases through immune checkpoint blockade and targeted therapy has significantly improved outcomes and patient survival. Yet, half of all patients continue to die from brain metastases despite use of these therapies and the addition of localized therapies like surgery and stereotactic radiosurgery. Novel treatments are needed to improve the morbidity and mortality associated with melanoma brain metastases. We have identified the inflammatory myddosomal pathway as a novel potential target of therapy in melanoma brain metastases, with gross upregulation in both tumor tissue and tumor-infiltrating immune cells. These cells display upregulation in MYD88, IRAK-1, IRAK-4, and downstream mediators of inflammatory activation at both the gene and protein level. We have previously shown the ability of the oral IRAK-4 inhibitor emavusertib (CA-4948) to penetrate the blood brain barrier and inhibit the myddosomal pathway in metastatic melanoma and primary CNS lymphoma. In this study we further show the capacity for IRAK-4 inhibition with emavusertib to improve the therapeutic efficacy of anti-PD-1 immune checkpoint blockade in melanoma brain metastases. Emavusertib in combination with anti-PD-1 therapy results in improved tumor-infiltrating lymphocyte recruitment, decreased myeloid derived suppressor cell function, and upregulation of interferon γ signaling resulting in improved survival in aggressive mouse models of melanoma brain metastases. This work supports the development of combination strategies of emavusertib with immune checkpoint blockade in melanoma brain metastases.
Risk factors for early-onset venous thromboembolism in pediatric inflammatory bowel disease
Putzeys, Caroline Chinchilla, Gautam, Nina , Ritchey, Andrew, Kimberly, A, Sharma, Umesh, Mirea, Lucia , Hamant, Laura, Michel, Hilary K., Hilow, Elizabeth, Patel, Ashish, Ali, Sabina , Adler, J , Moses, Jonathan , Pasternak, Brad , Pasternak, Brad , Chinchilla Putzeys, Caroline , Kimberly, Amanda , Michel, Hilary K. , Ali, Sabina A.

Mayo Clinic

Crohn’s & Colitis 360 | June 23, 2026 | Volume: 8 | Issue: 3 | Pages: No page available

10.1093/crocol/otag034 | PMID 42583332 Get It

Abstract Background Inflammatory bowel disease (IBD) can lead to a hypercoagulable state, particularly at initial diagnosis. Consequently, venous thromboembolism (VTE) represents a serious complication associated with IBD. For children, the risk of VTE near the time of IBD diagnosis has not yet been quantified, and guidance for VTE prophylaxis remains unclear. Methods This multisite matched case-control study examined pediatric patients with a new diagnosis of IBD from 2019-2024. Cases were those who developed VTE ≤30 days prior or ≤90 days post IBD diagnosis. Controls were newly diagnosed IBD patients without VTE. Each case was matched to 2-6 controls based on IBD subtype and age at IBD diagnosis. Demographics, laboratory values, prothrombotic risk factors and treatments were compared between matched cases and controls using conditional logistic regression stratified, by case sets. Results Study subjects included 15 cases and 52 controls, resulting in 70 matched pairs. Factors associated with early VTE included lower hemoglobin (P = .003), lower albumin (P = .002), corticosteroids use (P = .01), central line (P = .002), and any surgery ≤90 days post IBD diagnosis (P = .001). No association with VTE was detected for platelets, C-reactive protein, fecal calprotectin, family history of IBD or body mass index. Conclusions Albumin, hemoglobin, steroid use, central line, and any surgery ≤90 days post IBD diagnosis were associated with early VTE. These risk factors may be used in a future prediction model to stratify newly diagnosed pediatric IBD patients by their risk for early VTE development.
19Aptamer-targeted delivery of siRNA therapeutics for cholangiocarcinoma
Kabashima, Ayano , Ozmert, Enis H, Driscoll, Julia, Carlson, Danielle M. , Doherty, Caroline , Kimball, Brooke, Millender, Jayla, Nishi, Hidemi , Gondaliya, Piyush , Patel, Tushar C, Maher, L James, Wilbanks, Brandon , Sample, Jack W. , Driscoll, Julia , Carlson, Danielle Marie , Kimball, Brooke , Millender, Jayla T. , Yan, Irene K. , Pearson, Keenan , Gores, Gregory J. , III, Louis James Maher , Smoot, Rory L.

Mayo Clinic

The Oncologist | June 23, 2026 | Volume: 31 | Issue: Supplement_1 | Pages: No page available

10.1093/oncolo/oyag205.020 Get It

Abstract Background and Objectives Cholangiocarcinoma (CCA) is an aggressive, highly lethal cancer of the biliary tract epithelium for which tumor resection is the only curative treatment. However, approximately half of patients present with nonresectable disease and median survival of these patients is just 8-12 months. A significant need exists for tumor-targeted therapeutics for patients with advanced disease who currently have limited treatment options. We aimed to address this need by developing an aptamer-targeted therapy for delivery of siRNAs inhibiting undruggable components of the Hippo pathway, a key driver of cholangiocarcinoma. Method We applied cell-SELEX against human CCA model cell line HuCCTl with negative selection against normal hepatocytes and cholangiocytes to identify an aptamer that selectively bound tumor cells. This aptamer, termed MC7122, was chemically modified to include fluorescent labels that enabled whole-animal biodistribution studies to assess in vivo selectivity. MC7122 was then deployed onto the surface of siRNA-loaded nanovesicles to drive tumor-targeted nucleic acid delivery. Tumor-bearing mice were treated with siRNAs three times per week for two weeks alone or in combination with standard of care chemotherapy. Results Combined treatment with siRNAs and standard of care chemotherapy reduced tumor burden in mice versus vehicle controls and slowed the spread of metastasis. Importantly, we found tumor-specific target gene knockdown without corresponding off-target knockdown in healthy surrounding liver tissue. Further, we demonstrated that sites in the lung, the primary location of metastasis in this model, were reduced not because of global target knockdown in lung but due to tumor-specific knockdown at the site of liver implantation. Conclusions Aptamer-guided vesicles represent a promising platform for targeted therapy delivery for previously undruggable targets. With this platform, tumor-selective therapies can be designed to exhibit exceptionally potent cytotoxicity, as healthy tissues remain unaffected by off-target effects. Future work will focus on refinement of therapeutic siRNA target selection and modification of nanovesicle components for enhanced levels of tumor specificity.
3BAP1 loss confers ferroptosis resistance to cholangiocarcinoma via TLCD1-mediated mitochondrial membrane phospholipid remodeling
Zhao, Yu, Classon, Peyton, Carlson, Danielle M. , Millender, Jayla T. , Abdelrahman, Amro M, Ilyas, Sumera I, Patel, Tushar C, Truty, Mark J. , Povero, Davide , Zhao, Yu, Classon, Peyton, Carlson, Danielle Marie , Yan, Irene K. , Ilyas, Sumera I. , Smoot, Rory L. , Gores, Gregory J.

Mayo Clinic

The Oncologist | June 23, 2026 | Volume: 31 | Issue: Supplement_1 | Pages: No page available

10.1093/oncolo/oyag205.004 Get It

Abstract Background Cholangiocarcinoma (CCA) is a deadly cancer of the hepatic bile duct epithelial cells. Loss-of-function mutations of epigenetic regulator ubiquitin C-terminal hydrolase deubiquitinase BRCA1associated protein 1 (BAP1) occur in 26-32% of human CCA and are associated with worse prognosis and resistance to cytotoxic therapy. The goal of this study is to identify how BAP1 loss promotes cell death evasion through metabolic rewiring. Materials and methods Isogenic wild-type and BAP1-deficient human and murine CCA cell lines were generated with shRNA/siRNA or CRISPR/Cas9 and were used to assess ferroptosis sensitivity by treatment with ferroptosis inducers. In vitro, ferroptosis was assessed by phospholipid peroxidation (C-11BODIPY), mitochondrial phospholipid peroxidation (MitoPeDPP, MitoCLox), iron overload (MitoFerro green) and cell death (CellTiter-Glo). Phospholipidomics and proteomics were performed in isogenic cells by LC-MS/MS. Syngeneic liver orthotopic CCA murine models and patient-derived xenografts (PDX) were used for in vivo pre-clinical studies. Results Our findings indicate that BAP1 loss confers CCA ferroptosis resistance. BAP1 loss protects CCA against mitochondrial iron overload, ROS accumulation, and phospholipid peroxidation. BAP1 loss protects from mitochondrial phospholipid peroxidation and cardiolipin oxidation. Unbiased phospholipidomic profiling revealed that BAP1 loss remodels membrane phospholipid composition, enriching for ferroptosis blocking monounsaturated phospholipids (MUFA-PLs) at the expense of ferroptosis-inducing polyunsaturated (PUFA-PLs). We found that BAP1 loss upregulates TLCD1, a phosphatidylethanolamine acyltransferase that incorporates MUFAs into membrane phospholipids, thereby stabilizing membranes against peroxidation. TLCD1 knockdown in ferroptosis-resistant BAP1-deficient CCA cells, restored ferroptosis sensitivity. Notably, TLCD1 is significantly upregulated in human BAP1-mutant CCA as compared to BAP1-expressing tumors. While not a mitochondrial protein, TLCD1 localizes in the ER and by the mitochondrial outer membrane, as demonstrated by our immunofluorescence analysis in human CCA cells. From a therapeutic perspective, we developed EpCAM (adhesion molecule highly expressed in CCA cells)-aptamer coated lactosomes packaged with siRNA against glutathione peroxidase 4 (GPX4), as a proof-of-concept strategy to safely induce ferroptosis selectively in CCA in vitro and in vivo. Administration of siGPX4-lactosomes in pre-clinical syngeneic liver orthotopic CCA murine models demonstrated a favorable safety profile, achieved robust intratumoral GPX4 knockdown (&gt;50%), exhibited optimal biodistribution, induced significant tumor lipid peroxidation, and resulted in reduced tumor burden. Lastly, ferroptosis inducer JKE-1674, combined with gemcitabine/cisplatin (Gem/Cis) significantly blocked tumor growth of Gem/Cis-resistant patient-derived xenografts. Conclusions Our findings reveal that BAP1 loss reprograms mitochondrial phospholipid metabolism thus conferring CCA resistance to ferroptosis, identifying TLCD1 as a targetable metabolic vulnerability in BAP1-mutant CCA. Additionally, our findings support ferroptosis inducing compounds as promising therapeutic approaches for CCA.
Phase I Study of Oncolytic Virus VV1 as Monotherapy or in Combination with Avelumab in Patients with Relapsed Refractory Solid Tumors
Merchan, Jaime R. , Patel, Manish R. , Cripe, Timothy P. , Old, Matthew , Boughton, Jen , Marcano, Rosa M. Diaz , Peng, Kah-Whye , Russell, Luke, Wiegert, Erol , Bexon, Alice S. , Powell, Steven , Old, Matthew O , Diaz Marcano, Rosa M , Russell, Stephen J , Russell, Luke , Packiriswamy, Nandakumar , Wiegert, Erol , Bexon, Alice S , Powell, Steven F

Mayo Clinic

Cancer Research Communications | June 22, 2026 | Volume: 6 | Issue: 8 | Pages: 1862-1874

10.1158/2767-9764.crc-25-0803 | PMID 42330318 Get It

Abstract Purpose: VV1 is designed to induce selective oncolysis of tumor cells and amplify cellular antitumor immune responses. This open-label, phase I, multicenter clinical trial assessed the safety and tolerability of VV1 monotherapy administered intratumorally or intravenously or administered intravenously in combination with avelumab. Patients and Methods: Patients with advanced solid tumors received intratumoral (n = 27) or intravenous VV1 monotherapy (n = 33) or intravenous VV1 plus avelumab (n = 16). Infusion durations (15–180 minutes) and viral dose (1.7 × 1010 or 1 × 1011 TCID50) were also evaluated. Study objectives included VV1 safety and tolerability, pharmacokinetics, pharmacodynamics, preliminary efficacy, and immune responses. Results: Intratumoral and intravenous VV1 were well tolerated, and injection reactions were infrequent. The most common adverse events of any grade related to VV1 were cytokine release syndrome (58%), fatigue (33%), and decreased lymphocyte count (32%). Virus infection of tumors was confirmed by NIS imaging and increases in serum levels of virally encoded interferon-β (IFNβ). Histologic tumor analysis at 28 days after intratumoral VV1 administration indicated increases in tumor-infiltrating immune cells. Two durable partial responses were recorded: a patient with pheochromocytoma after one intravenous dose of VV1 and a patient with thymic cancer in the combination arm. Stable disease was observed in 17 of 49 patients (34.7%) who received intravenous VV1. Conclusions: This first-in-human study demonstrates that intratumoral or intravenous VV1 administration had an acceptable safety profile as monotherapy and intravenously in combination with avelumab. There is preliminary antitumor activity. Intratumoral VV1 plus cemiplimab is now showing promise in the neoadjuvant setting. Significance: VV1 is a tumor-selective oncolytic vesicular stomatitis virus engineered to express IFNβ and the thyroidal NIS reporter gene. In this phase I study, we have demonstrated that a single administration of VV1, as a monotherapy or with an immune checkpoint inhibitor is safe, infects tumor lesions resulting in intratumoral infiltration of immune cells, and exhibits early signs of antitumor activity in patients with advanced unresectable and metastatic solid tumors.
A75-20 Analysis of Data From a Prospective Medicare Approved Clinical Trial Registry Indicates That Use of Maintenance Extracorporeal Photopheresis Is Independently Associated With Enhanced Survival of Lung Allograft Recipients Who Have Developed Life-Thre
Despotis, G J, Hachem, R R, Hage, C A, Walia, R, Goldberg, H J, Patel, M, Reynolds, J M, Klesney-Tait, J, Arcasoy, S M, Naik, C, Simone, N De, Usmani, A, Girgis, R E, Cordova, F C, Keller, B C, Nunley, D R, Javanbakht, A, Patil, J M, Morrell, M R, Lendermon, E A, Huang, H J, Pelaez, A, Emtiazjoo, A, Wille, K M, Chan, K M, Yung, G, Baz, M A, Aryal, S, Banez-Sese, G, Vedantham, S, Derfler, C, Commean, P, Berman, K, Atkinson, A, Atkinson, J J, Prokudin, A, Betensley, A D, Byers, D E, Despotis, G. J., Hachem, Ramsey R. , Hage, C A, Walia, Rajat , Reynolds, J.M., Klesney‐Tait, Julia , Arcasoy, S M, Naik, C., Girgis, Reda E. , Cordova, F C, Keller, Brian C. , Nunley, D R, Patil, Jagadish , Morrell, M R, Lendermon, Elizabeth A. , Huang, H J, Emtiazjoo, A.M., Wille, Keith , Chan, K.M., Yung, G, Baz, Maher A. , Aryal, S, Banez‐Sese, Grace, Vedantham, Suresh , Berman, Keith, Prokudin, A, Betensley, Alan D. , Byers, Derek E.

Mayo Clinic

American Journal of Respiratory and Critical Care Medicine | June 22, 2026 | Volume: 212 | Issue: Supplement_2 | Pages: No page available

10.1093/ajrccm/aamag286.333 Get It

Abstract Rationale This Registry was designed to prospectively evaluate the efficacy of extracorporeal photopheresis (ECP) to arrest the rate of FEV1 decline (FEV1 decline) and prolong survival in lung allograft recipients with Bronchiolitis Obliterans refractory to standard of care therapy. Methods After IRB approval, 258 lung transplant recipients were enrolled from 20 US lung transplant centers. Subjects were assigned to ECP treatment (ECPRx) (i.e., 24 procedures over 6 months) at or a few months after enrollment based on spirometric criteria. Maintenance ECPRx (mECP) was at the discretion of managing clinicians. Rate of FEV1 decline in mL/month (FEV1 decline) was compared between 6 months prior to and 6 & 12 months after ECPRx initiation using linear mixed effects models. Time 0 for survival was set as the start of ECPRx for generation of Kaplan-Meier curves. Hazard Ratios (HR) with 95% confidence intervals (lower-upper) were generated using Cox Proportional Hazards Regression to characterize significant (p &lt; 0.05) independent associations of mECP and/or any other covariates (i.e., demographic, operative, enrollment site, spirometric ) and survival. Results An 89% (78%-96%) decrease in the FEV1 decline was observed 12 months after ECPRx initiation in 191 participants assigned to ECPRx. FEV1 decline (-164 mL/month: 144-185) was greater (p &lt; 0.001) in participants who expired within six months of Time 0 (n = 28) vs participants (-111 mL/month: 101-120) who died six months after Time 0 (n = 77). Of 159 participants who survived for at least six months after ECPRx initiation, 40 participants without mECP, who had up to 24 ECPRx (ECPRx: n = 19), had a lower survival HR: 2.43(1.75-3.4) (p &lt; 0.001) relative to 119 participants who received mECP (ECPRx: n = 86)(see Figure). The response to ECPRx (% Change in FEV1 decline prior to and 6 months after 1st ECP) was similar between subcohorts (No mECP: -81 decrease vs mECP: -85%, p = 0.3). The association of mECP persisted after multivariate adjustment HR 1.8 (1.8-2.7)(p = 0.002) using significant covariates: FEV1 HR 0.37 (0.3-0.5), FEV1 decline HR 0.001 (0.001-0.04), Male Gender HR 2.4 (1.7-3.4); Reflux Disease HR 1.8 (1.2-2.8); Coronary Disease HR 1.8 (1.2-2.7). Conclusions This analysis indicates that mECP is independently associated with enhanced survival most likely due to attenuation of relapse six months after ECP initiation based on similar initial response to ECPRx. A risk-adjusted, control cohort is being pursued to facilitate submission of a scientifically rigorous petition to CMS to expand the ECP National Coverage Decision to include BOS predicated on CMS 2024 scientific guidelines. This abstract is funded by: Therakos Inc